News

JIC Venture Growth Investments has invested in Alivexis Inc. (Headquarter: Minato-ku, Tokyo; CEO: S. Roy Kimura; hereinafter referred to as "Alivexis"), through its JIC Venture Growth Fund 2.

‍

Alivexis is a technology-driven drug discovery company with operational bases in Japan and the United States. By merging state-of-the-art drug discovery platforms with profound knowledge of disease biology and a dynamic global business approach, Alivexis is propelling forward its distinct portfolio of small molecule drugs along with a variety of research and development collaborations. Its proprietary drug discovery platform, ModBind™, powered by cutting-edge computational science, enables accurate absolute ligand binding predictions at speeds up to 2,000 times faster than conventional methods. Leveraging this technology, Alivexis is dedicated to swiftly bringing innovative medications to individuals and their families grappling with cancer, both chronic and acute immune-inflammatory diseases, and rare conditions.

‍

The significance of this investment lies in addressing unmet medical needs through the development of innovative small molecule therapies. By integrating Alivexis’s strengths in computational science with the rapidly evolving field of AI-driven drug discovery, the company is expected to create new applications for AI and semiconductor technologies. Furthermore, Alivexis aims to become a successful example of a global drug discovery startup originating from Japan, contributing to the revitalization of the drug discovery ecosystem.

‍

Through this investment, JIC Venture Growth Investments seeks to support Alivexis in advancing its proprietary drug discovery programs and accelerating its networked R&D efforts powered by the ModBind™ platform. By doing so, we aim to help the company fulfill its mission of expediting the discovery of novel medicines for patients and families in need, while simultaneously contributing to the growth of Japan's drug discovery venture ecosystem.

‍

_{The information contained in this notice is current at the time of publication and subject to change without notice.}